StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
| March 17, 2025 | Financial Results Presentation Materials | Presentation Materials for Six Months Ended January 31, 2025 |
|---|---|---|
| March 12, 2025 | Financial Results | Non-consolidated Financial Results for the Six Months Ended January 31, 2025 [Japanese GAAP] |
| March 03, 2025 | Timely Disclosure Information | StemRIM Announces the Protocol Amendment for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke |
| January 15, 2025 | Timely Disclosure Information | StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms |
| December 23, 2024 | Timely Disclosure Information | StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy |
| April 25, 2023 | NEWS Release |
|---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
